GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akebia Therapeutics Inc (NAS:AKBA) » Definitions » Total Inventories

Akebia Therapeutics (Akebia Therapeutics) Total Inventories : $15.7 Mil (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics Total Inventories?

Akebia Therapeutics's total inventories for the quarter that ended in Dec. 2023 was $15.7 Mil. Akebia Therapeutics's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $17.1 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Akebia Therapeutics's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-0.99.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Akebia Therapeutics's Days Inventory for the three months ended in Dec. 2023 was 83.44.

Inventory Turnover measures how fast the company turns over its inventory within a year. Akebia Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 was 1.09.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Akebia Therapeutics's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.30.


Akebia Therapeutics Total Inventories Historical Data

The historical data trend for Akebia Therapeutics's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akebia Therapeutics Total Inventories Chart

Akebia Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Total Inventories
Get a 7-Day Free Trial Premium Member Only Premium Member Only 116.35 61.02 36.63 21.57 15.69

Akebia Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Total Inventories Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.57 20.60 20.91 18.44 15.69

Akebia Therapeutics Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.


Akebia Therapeutics  (NAS:AKBA) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Akebia Therapeutics's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

Net-Net Working Capital Per Share (Q: Dec. 2023 )
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(42.925+0.75 * 39.29+0.5 * 15.691-272.287
-0-0)/194.583
=-0.99

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Akebia Therapeutics's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Dec. 2023 )/Cost of Goods Sold (Q: Dec. 2023 )*Days in Period
=17.0665/18.665*365 / 4
=83.44

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Akebia Therapeutics's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Dec. 2023 ) / Average Total Inventories (Q: Dec. 2023 )
=18.665 / 17.0665
=1.09

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Akebia Therapeutics's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue=Average Total Inventories (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=17.0665 / 56.196
=0.30

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.


Akebia Therapeutics Total Inventories Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.


Akebia Therapeutics (Akebia Therapeutics) Business Description

Traded in Other Exchanges
Address
245 First Street, Cambridge, MA, USA, 02142
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.
Executives
Ellen Snow officer: SVP, CFO and Treasurer C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Michel Dahan officer: SVP, Chief Business Officer C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Nicole R. Hadas officer: SVP, General Counsel, Sec. 20 PILGRAM DRIVE, WINCHESTER MA 01890
David A Spellman officer: SVP, CFO and Treasurer 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Steven Keith Burke officer: SVP, Chief Medical Officer 82 WILLIS ROAD, SUDBURY MA 01776
John P. Butler director, officer: CEO & President C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Violetta Cotreau officer: SVP, Chief Accounting Officer 245 FIRST STREET, 14TH FLOOR, CAMBRIDGE MA 02142
Ron Frieson director 245 FIRST STREET, 14TH FLOOR, CAMBRIDGE MA 02142
Dell Faulkingham officer: CCO C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Leanne M Zumwalt director C/O THE ADVISORY BOARD CO WATERGATGE, 600 NEW HAMPSHIRE AVE NW, WASHINGTON DC 20037
Maxine Gowen director
Cynthia Smith director 508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Myles Wolf director C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Karen L Tubridy officer: SVP, Chief Development Officer ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142